Neurol. praxi. 2015;16(4):215-218

Chronic inflammatory demyelinating polyradiculoneuropathy

doc. MUDr. Edvard Ehler, CSc.
Neurologická klinika PKN, a.s. a Fakulta zdravotnických studií Univerzity Pardubice

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by relapsing or progredient course. This is an autoimmune polyradiculoneuropahty with activation of cellular and humoral mechanisms and with primary lesion of myelin sheath in peripheral nerves. Demyelinating and remyelinating changes could be disclosed by nerve biopsy, or their equivalent proved with help of neurophysiological investigation. In clinical finding there is motor nerve disorder in distal and also proximal regions, in typical form in all four extremities, disturbances of sensitive and autonomic nerves are present. Besides the most frequent typical form there are more not so frequent forms. In CIDP therapy corticosteroids are used most frequently, then intravenously administered immunoglobulins and only in restricted indication plasmapheresis. CIDP is a treatable neuropathy, though in substantial proportion of patients leads to invalidity. of immunoglobulins.

Keywords: polyradiculoneuritis, autoimmune inflammation, neurophysiological investigation, nerve biopsy, intravenous administration

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ehler E. Chronic inflammatory demyelinating polyradiculoneuropathy. Neurol. praxi. 2015;16(4):215-218.
Download citation

References

  1. Ambler Z. Poruchy periferních nervů. Praha: Triton, 2013.
  2. Ambler Z, Bednařík J. Léčba první volby u CIDP, kortikoidy nebo IVIG? Neurol. praxi 2013; 114(4): 210-211.
  3. Amato AA, Russell JA. Neuromuscular disorders. New York: McGraw Hill, 2008.
  4. Bednařík J, Voháňka S, Ehler E, Ambler Z, Piťha J, Vencovský J, Litzman J, Kořístek Z, Suchý M, Pátá M, Kožený P. Standard pro léčbu pacientů s autoimunitními nervosvalovými onemocněními intravenózním lidským imunoglobulinem a plazmaferézou. Ces Slov Neurol N 2010; 73: 579-586.
  5. Bright RJ, Wilkinson J, Coventry BJ. Therapeutic option for chronic inflammatory demyelinating polyradiculoneuropathy. BMS Neurology 2014; 14: 26-35. Go to original source... Go to PubMed...
  6. Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thomůpson AR, Krueger A, Sanders DB. Patient demographics and health plan paid costs in chronic inflammatofry demyelinating polyneuropathy. Muscle Nerve 2014; 50: 47-51. Go to original source...
  7. Hughes RAC, Allen D, Makowska Anna, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the peripheral nervous systém 2006; 11: 30-46. Go to original source... Go to PubMed...
  8. Hughes, RAC, Donofrio P, Brill V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, ICE Study group. Intravenous immune globulin (10 % caprylate chromatography purified) for the treatment of the chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placeb-controlled trial. Lancet Neurol 2008; 7(2): 136-144. Go to original source...
  9. Jo HZ, Park MG, Kim GS, Nam SO, Park KH. Chronic demyelinating inflammatory polyradiculoneuropathy in children: characterized by subacute, predominantly motor dominant polyneuropathy with a favorable response to the treatment. Acta Neurol Scand 2010; 121: 342-347. Go to original source... Go to PubMed...
  10. Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, Gorson K, Hahn AF, Hughes RA, Katz J, Lewis RA, Parry GJ, van Doorn P, Cornblath DR. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009; 277: 1-8. Go to original source...
  11. Markvardes LH, Harbo T, Sindrup SH, Christiansen I, Andersen H, Jakobsen J, The Danish CIDP and MMN Study Group. Eur J Neurol 2014; Jul 7. doi: 10.1111/ene.12513. Go to original source... Go to PubMed...
  12. Melzer N, Meuth SG. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clinical and experimental imunology 2013; 175: 359-372. Go to original source...
  13. Misra UK, Kalita J, Yadav RK. A comparison of clinically atypical and typice chronic inflammatory demyelinating polyradiculoneuropathy. Europ Neurol 2007; 58: 100-105. Go to original source... Go to PubMed...
  14. Overell JL, Willison HJ. Chronic inflammatory polyradiculoneuropaty: classification and treatment. Practical Neurology 2006; 6: 102-110. Go to original source...
  15. Pourmand R. Immune-mediated neuromuscular diseases. Basel: Karger, 2009. Go to original source...
  16. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412. Go to original source...
  17. Van den Bergh PYK, Hadden RMD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Léger JM, Nbile-Oracio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and Peripheral Nerve Society - First Revision. European Journal of Neurology 2010; 17: 356-363. Go to original source... Go to PubMed...
  18. Van den Bergh PY, Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med 2013; 42: 203-215. Go to original source... Go to PubMed...
  19. Viala K, Maisonobe T, Stojkovic T, Koutlidis R, Ayrignac C, Musset L, Fournier E, Léger JM, Bouche P. A current view of the diagnosis, clinical variants, response to treatment and prognosis of the chronic inflammatory demyelinating polyradiculoneuropathy. J of Peripheral Nervous System 2010; 15: 50-56. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.